Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Humacyte ( (HUMA) ) has shared an update.
On December 15, 2025, Humacyte, Inc. and Humacyte Global, Inc. reached an agreement with TPC Investments III LP and TPC Investments Solutions LP to terminate their existing Revenue Interest Purchase Agreement and Option Agreement. As part of this termination, Humacyte will pay $38 million in cash and issue over 5.7 million shares of common stock to the Purchasers, with the cash payment expected to be funded by a new credit facility. This strategic move is anticipated to impact Humacyte’s financial operations and market positioning, as it involves a significant financial transaction and issuance of shares.
The most recent analyst rating on (HUMA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.
Spark’s Take on HUMA Stock
According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.
Humacyte’s overall stock score reflects significant financial and technical challenges. The lack of revenue, persistent losses, and negative equity weigh heavily on the financial performance. Technical analysis indicates bearish momentum. The valuation metrics suggest the stock may be overpriced given the negative P/E ratio and absence of dividends. The earnings call offered some optimism regarding future growth due to FDA approvals and product launches, but these are long-term prospects amid current financial difficulties. Recent corporate events provide mixed signals with potential legal risks and a successful capital raise.
To see Spark’s full report on HUMA stock, click here.
More about Humacyte
Humacyte, Inc. operates in the biotechnology industry, focusing on the development and commercialization of bioengineered human tissues and organs. The company’s primary products include regenerative medicine solutions aimed at improving patient outcomes across various medical conditions.
Average Trading Volume: 5,386,111
Technical Sentiment Signal: Sell
Current Market Cap: $245.3M
Find detailed analytics on HUMA stock on TipRanks’ Stock Analysis page.